The world’s biggest trial of Grail Inc’s (GRAL.O) flagship Galleri blood test will begin from Monday in Britain’s state-run National Health Service which may help to detect more than 50 types of cancer before symptoms appear.

Because earlier diagnosis of cancers leads to dramatically increased survival rates, The Galleri test helps to look at the DNA in a patient’s blood to determine if any come from cancer cells.

The NHS stated that it wanted to recruit 140,000 volunteers in England to check how well the test works as part of a randomised control trial. Half of the participants will have their blood sample screened with the Galleri test right away.

Peter Sasieni, professor of cancer prevention at King’s College London said, “We need to study the Galleri test carefully to find out whether it can significantly reduce the number of cancers diagnosed at a late stage”.

“The test could be a game changer for early cancer detection and we are excited to be leading this important research.”

Lung cancer is considered to be the most common cause of cancer death in the United Kingdom, accounting for around a fifth of all cancer deaths. Lung, bowel, prostate and breast cancers account for 45% of the United Kingdom’s cancer deaths, the NHS said.

U.S. life sciences company Illumina Inc (ILMN.O) said last month it had completed its $7.1 billion acquisition of Grail. Illumina said it will operate Grail separately from its existing business.